Aroma Bit Receives Additional Capital Investment Funding From Epson X Investment, Kyocera, and TechAccel Ventures
9.2.2021 09:00:00 EET | Business Wire | Press release
Aroma Bit, Inc., (Representative Director & CEO: Shunichiro Kuroki, headquarters: Chuo-ku, Tokyo), develops and markets compact odor imaging sensors and various related innovative services, has allocated additional shares to third-parties. The purpose of the funding is to acquire growth funds needed for future functionality enhancements of the company’s compact odor sensors and development of mass production capabilities, business development, and etc. EB-GB Limited Partnership funded by Epson X Investment Corporation (Representative Director: Yasunori Ogawa, headquarters: Chiyoda-ku, Tokyo), Kyocera Corporation (President: Hideo Tanimoto, headquarters: Kyoto City, Kyoto), and TechAccel investment limited partnership 1 (fund operated by TechAccel Ventures, LLC (Functional Manager: Masatoshi Ohba, headquarters: Minato-ku, Tokyo)) are the investment partners participating in this new capital investment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005274/en/
Silicon CMOS type Smell Sensor Development Kit (Product ID: 5C-SSM) (Photo: Business Wire)
Aroma Bit, Inc.: http://www.aromabit.com
Purpose and background of the increased capital investment: Support for acceleration of the compact odor sensors’ mass production and expansion of the digital odor sensing market
Aroma Bit has developed the world’s first compact odor imaging sensor that digitizes odors with visualization patterns from various odor inputs, similar to an animal’s sense of smell. It differs from conventional gas sensors, which can only detect specific substances.
Despite COVID-19, Aroma Bit has seen an increase in business negotiations with customers both in Japan and internationally accelerated by emerging trends such as smart technology, contactless technology, and digital transformation (DX).
Furthermore, the device has a wide range of applications, including the food, agriculture, daily commodities, industrial machinery, mobility, healthcare, robotics, mobile information service, home electronics, and IoT industries. With market applications exceeding initial expectations, there is considerable potential demand for odor digitization using Aroma Bit’s innovative technology.
After this third-party allocation of new shares, Aroma Bit plans to collaborate with major electronic device companies with advanced manufacturing expertise to accelerate development and mass production of compact odor sensor technologies.
Additionally, Aroma Bit plans to strengthen development of new products and services that leverage the company’s proprietary odor databases, and expand its sales and marketing worldwide.
In the future, Aroma Bit will continue to pursue its vision of “Enrich Society by Creating a World where Odors and Aromas are Visualized through Digital Odor Sensing Technology.”
Release of development kit for silicon CMOS compact odor sensors
Aroma Bit launched its silicon CMOS sensor module development kit [5C-SSM-H1] in January of 2021. Those sensors feature 80 elements arranged on a 6 mm x 3 mm silicon chip (5 types of odor-sensitive membrane x 16 elements per membrane). Aroma Bit Silicon Sensor Technology, Inc., a subsidiary of Aroma Bit manages sales for these devices.
With the release of the silicon CMOS odor sensor, Aroma Bit anticipates increased demand in high-volume consumer applications such as mobile devices, mobility, and home electronics, where its other QCM odor sensor use was previously difficult due to factors such as price and usage environment.
About Aroma Bit
Aroma Bit is a company that plans, develops, and sells electronic devices such as compact odor sensors as well as innovative new services that use these devices.
|
[Company Profile] |
||
|
Company name: |
|
Aroma Bit, Inc. |
|
Location: |
|
Sagami Bldg. 2F, 7-13-6 Ginza, Chuo-ku, Tokyo |
|
Representative: |
|
Representative Director & CEO Shunichiro Kuroki |
|
Established: |
|
February 2014 |
|
Business: |
|
Development, production, and sales of electronic equipment and systems including compact odor imaging sensors |
|
|
|
Planning, development, and sales of products and innovative services that use the sensor products |
|
|
|
Other business related to the above |
|
URL: www.aromabit.com |
||
About Epson X Investment
Epson X Investment Corporation is a Corporate Venture Capital (CVC) firm wholly owned by information equipment and precision instrument manufacturer Seiko Epson Corporation. It established the “EP-GB Investment Limited Partnership” with independent venture capital firm Global Brain Corporation, which has strengths in CVC operations, as general partner and is conducting investment activities.
URL: https://www.epson-exi.com/
Kyocera Corporation (TOKYO:6971, https://global.kyocera.com/), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2020, the company’s consolidated sales revenue totaled 1.6 trillion yen (approx. US$14.7 billion). Kyocera is ranked #549 on Forbes magazine’s 2020 “Global 2000” list of the world’s largest publicly traded companies.
About TechAccel Ventures
TechAccel Ventures, LLC is a venture capital firm established and operated by Omron, Ricoh, and SMBC Venture Capital. It invests mainly in tech venture companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005274/en/
Contact information
[Inquiries regarding this announcement]
Aroma Bit, Inc.
Public Relegations Department (Matsumoto, Osamu)
TEL: +81-3-4455-4609 / Email: info@aromabit.com
Epson X Investment Corporation
Seiko Epson PR & IR Department (Muto, Nobuo)
TEL: +81-266-58-1705 or +81-3-5368-0961 / Email: info@press.epson.co.jp
KYOCERA Corporation
Corporate Communications (Usami, Masaru)
TEL: +81-75-604-3514 / Email: webmaster.cc@kyocera.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom